Drugs / Imipenem/Cilastatin/Relebactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05561764 | Jan 2023 → Oct 2024 | bacterial pneumonia, cystic fibrosis | Hartford Hospital | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-04-22 | Merck Sharp & Dohme LLC | Results Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Demonstrated Favorable Overall Response Against Certain Imipenem–Non-Susceptible Bacterial Infections merck.com ↗
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a pivotal Phase 3 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin, demonstrated a favorable overall response in the treatment of certain imipenem–non-susceptible bacterial infections, the primary endpoint, with lower treatment-emergent nephrotoxicity (kidney toxicity), a secondary endpoint, compared to a Colistin (colistimethate sodium) plus imipenem regimen. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imipenem/Cilastatin/Relebactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561764 ↗ |
| Route | Intravenous | “Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.” NCT05561764 ↗ |